CJC-1295
CJC-1295 with DAC (Drug Affinity Complex)
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) designed to stimulate natural growth hormone production from the pituitary gland. Its unique Drug Affinity Complex (DAC) modification allows it to bind to albumin, extending its half-life to 6-8 days and enabling sustained pulsatile growth hormone release. Unlike direct growth hormone therapy, CJC-1295 works with the body's natural rhythms to optimize anabolic effects while maintaining physiological hormone patterns.
Complete Research Database
Adverse Event Frequencies (Clinical Trials)
Clinical Safety Notes
- •GI side effects typically occur during dose escalation
- •Most adverse events are mild to moderate in severity
- •Discontinuation rate due to side effects: ~5.3%
- •No increased risk of pancreatitis in clinical trials
- •Regular monitoring recommended for thyroid function
Medical Disclaimer
CJC-1295 is an investigational research compound not approved by the FDA for human therapeutic use. This information is for educational purposes only and should not be construed as medical advice. Any use should occur only under medical supervision in approved research settings. Long-term effects are not well-studied in humans.